Skip to main navigation Skip to search Skip to main content

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up

  • Hagop Kantarjian
  • , Jorge Cortes
  • , Dong Wook Kim
  • , Pedro Dorlhiac-Llacer
  • , Ricardo Pasquini
  • , John DiPersio
  • , Martin C. Müller
  • , Jerald P. Radich
  • , H. Jean Khoury
  • , Nina Khoroshko
  • , M. Brigid Bradley-Garelik
  • , Chao Zhu
  • , Martin S. Tallman

Research output: Contribution to journal › Article › peer-review

162   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science